InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort

STATUS

Recruiting
participants needed

48
sponsor

Revimmune

Send

Updated on 19 February 2024

See if I qualify

intermittent positive pressure ventilation

covid-19

interleukins

respiratory failure

invasive positive pressure ventilation

absolute lymphocyte count

interleukin-7

Summary

Comparison of the effects of CYT107 vs Placebo administered IM at 10g/kg twice a week for two weeks on immune reconstitution of lymphopenic COVID-19 patients.

Description

Approximately forty-eight (48) participants will be randomized 1:1 to receive (a) Intramuscular (IM) administration of CYT107 at 3 g/kg followed, after 48hrs of observation, by 10 g/kg twice a week for 2 weeks or (b) Intramuscular (IM) placebo (normal saline) at the same frequency. An interim safety review will take place after the first 12 patients. If the CYT107 is well tolerated, the test dose (3 g/kg) will cease and that initial dose will become the same as the rest of the doses (10 g/kg). So, the remaining patients will be randomized to receive 5 administrations of (a) CYT107 at 10 g/kg every 3 to 4 days for 2 weeks or (b) Intramuscular (IM) placebo (normal saline) at the same frequency.

The aim of the study is to test the ability of CYT107 to produce an immune reconstitution of these patients and observe possible association with a clinical improvement

Details

Condition	Lymphopenia, Covid 19
Age	25years - 80years
Treatment	Placebos, Interleukin-7
Clinical Study Identifier	NCT04379076
Sponsor	Revimmune
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	A written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing Study participation
	Men and women aged 25 - 80 (included) years of age
	Hospitalized patients with two absolute lymphocyte count (ALC) 1000 cells/mm3, at two time points at least 24 hours apart, following HOSPITALIZATION
	The FIRST time point should not be performed earlier than 48 hours after
	Hospitalization, thus first test dose can't be administered before 72 hours
	after hospitalization (From this time point the investigator may choose to
	further postpone the commencement of IL-7 (CYT107) treatment according to
	patient's clinical status)
	Hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at >4L per minute nasal cannula or greater to keep saturations >90%, non-invasive positive pressure ventilation (e.g., BIPAP), or patients intubated/ventilated for respiratory failure
	Confirmed infection with COVID-19 by any acceptable test available/utilized at each site
	Private insurance or government support (through NHS or other)
Exclusion Criteria
	Pregnancy or breast feeding
	Refusal or inability to practice contraception regardless of the gender of the patient
	ALT and/or AST > 5 x ULN
	Known, active auto-immune disease
	Ongoing cancer treatment with chemotherapy / immunotherapy or any cancer therapy within last 3 months and/or ongoing
	Patients with past history of Solid Organ transplant
	Active tuberculosis, uncontrolled active HBV or HCV infection, HIV with positive viral load
	Hospitalized patients with refractory hypoxia, defined as inability to maintain saturation >85% with maximal available therapy for >6 hours
	Patients receiving any agent with immune suppressive effects, other than steroids at dosages less than 300 mg/day and/or anti-IL6 treatments like Tocilizumab or Sarilumab which should preferably be minimized
	Patients with baseline Rockwood Clinical Frailty Scale 6
	Patients under guardianship

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

intermittent positive pressure ventilation

covid-19

interleukins

respiratory failure

invasive positive pressure ventilation

absolute lymphocyte count

interleukin-7

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort